Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

Inclusion criteria : * The participant and/or participant's parent(s)/legal guardian(s) must provide written informed assent/consent prior to any protocol-related procedures being performed. * The participant was \<18 years of age on the date of informed assent/consent. * The participant had documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes. * The participant had a spleen volume greater than or equal to (\>=) 5 multiples of normal (MN) measured by magnetic resonance imaging (MRI); participants who had partial splenectomy were allowed if the procedure was performed \>=1 year before screening and the residual spleen volume was \>=5 MN. * The participant's height was -1 Z-score or lower. * A negative serum pregnancy test in female participants of childbearing potential. * Female participants of childbearing potential and male participants must be willing to practice true abstinence in line with their preferred and usual lifestyle or use 2 acceptable effective methods of contraception. Exclusion criteria: * The participant had received an investigational drug within 30 days before study enrollment. * The participant had any of the following medical conditions: * An active, serious, intercurrent illness. * Active hepatitis B or hepatitis C infection. * Infection with human immunodeficiency virus (HIV). * Cirrhosis (determined by clinical evaluation). * Significant cardiac disease (eg, clinically significant…